Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 11/20 | 0.45 |
| ▸ | ACACA | Q13085 | 11/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11932139 | 0.92 | ACACB (0.52) | ACACBACACACHRM2CHRM4CHRM5 | |
| SCHEMBL12778736 | 0.92 | ACACB (0.52) | ACACBACACACHRM2CHRM4CHRM5 | |
| SCHEMBL14501904 | 0.90 | ACACB (0.42) | ACACBACACACHRM2CHRM4CHRM5 | |
| SCHEMBL13266752 | 0.90 | ACACB (0.42) | ACACBACACACHRM2CHRM4CHRM5 | |
| SCHEMBL13105390 | 0.89 | ACACB (0.41) | ACACBACACACHRM2CHRM4CHRM5 | |
| SCHEMBL2850592 | 0.84 | ACACB (0.52) | ACACBACACACHRM2CHRM4CHRM5 | |
| SCHEMBL2850600 | 0.83 | ACACB (0.54) | ACACBACACACHRM2CHRM4CHRM5 | |
| SCHEMBL2850595 | 0.83 | ACACB (0.54) | ACACBACACACHRM2CHRM4CHRM5 | |
| SCHEMBL15894937 | 0.82 | ACACB (0.51) | ACACBACACACHRM2CHRM4CHRM5 | |
| SCHEMBL13527319 | 0.82 | ACACB (0.51) | ACACBACACACHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7727933-B2 | 2-ethyl-4,6-dimethyl-phenyl-substituted spirocyclic tetramic acid derivatives | BAYER CROPSCIENCE AG (DE) | 2010-06-01 | — | — | US | disclosed |
| US-20070298969-A1 | 2-Ethyl-4,6-Dimethyl-Phenyl-Substituted Spirocyclic Tetramic Acid Derivatives | BAYER CROPSCIENCE AKTIENGESELLSCHAFF (DE) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070298969-A1 | 2-Ethyl-4,6-Dimethyl-Phenyl-Substituted Spirocyclic Tetramic Acid Derivatives | DDT, PKD2, CYP2D6 | ACACB 1784/4885ACACA 1730/4885CHRM2 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.